SubtlePETTM is FDA-cleared for use with 18F-FDG and 18F-Amyloid tracers and, since june 2021, is now CE-marked for use with 18F-FDG, 18F-Amyloid, 18F-Fluciclovine, 18F-DOPA, 18F-Choline, 18F-DCFPyL, Ga-68 Dotatate and Ga-68 PSMA radiotracer PET images, expanding coverage for Prostate (PSMA) and Neuroendocrine tumors. Here, FOLH1 is linked to neuroendocrine neoplasm.